{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:40:34Z","timestamp":1787010034539,"version":"build-2736575974"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T00:00:00Z","timestamp":1636588800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,3]]},"abstract":"\n Objective:<\/jats:title>\n The need for pediatric antifungal stewardship programs has been driven by an increasing consumption of antifungals for prophylactic and empirical use. Drivers and rational of antifungal prescribing need to be identified to optimize prescription behaviors.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n A prospective modified weekly Point Prevalence Survey capturing antifungal prescriptions for children (> 90 days to < 18 years of age) in 12 centers in England during 26 consecutive weeks was performed. Demographic, diagnostic and treatment information was collected for each patient. Data were entered into an online REDCap database.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n One thousand two hundred fifty-eight prescriptions were included for 656 pediatric patients, 44.9% were girls, with a median age of 6.4 years (interquartile range, 2.5\u201311.3). Most common underlying condition was malignancy (55.5%). Four hundred nineteen (63.9%) received antifungals for prophylaxis, and 237 (36.1%) for treatment. Among patients receiving antifungal prophylaxis, 40.2% did not belong to a high-risk group. In those receiving antifungal treatment, 45.9%, 29.4%, 5.1% and 19.6% had a diagnosis of suspected, possible, probable of proven invasive fungal disease (IFD), respectively. Proven IFD was diagnosed in 78 patients, 84.6% (n = 66) suffered from invasive candidiasis and 15.4% (n = 12) from an invasive mold infection. Liposomal amphotericin B was the most commonly prescribed antifungal for both prophylaxis (36.6%) and empiric and preemptive treatment (47.9%). Throughout the duration of the study, 72 (11.0%) patients received combination antifungal therapy.<\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n Antifungal use in pediatric patients is dominated by liposomal amphotericin B and often without evidence for the presence of IFD. A significant proportion of prophylactic and empiric antifungal use was seen in pediatric patients not at high-risk for IFD.<\/jats:p>\n <\/jats:sec>","DOI":"10.1097\/inf.0000000000003402","type":"journal-article","created":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T14:04:35Z","timestamp":1637071475000},"page":"e69-e74","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":24,"title":["Pediatric Antifungal Prescribing Patterns Identify Significant Opportunities to Rationalize Antifungal Use in Children"],"prefix":"10.1097","volume":"41","author":[{"given":"Laura","family":"Ferreras-Antol\u00edn","sequence":"first","affiliation":[{"name":"Medical Research Council Centre for Medical Mycology, University of Exeter, United Kingdom"},{"name":"St George\u2019s University Hospitals NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Irwin","sequence":"additional","affiliation":[{"name":"Department of Paediatric Infectious Diseases, Great Ormond Street Hospital for Children, London, United Kingdom"},{"name":"The University of Queensland Centre for Clinical Research, Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayad","family":"Atra","sequence":"additional","affiliation":[{"name":"Department of Paediatric Oncology, Royal Marsden Hospital, Downs Road, Sutton, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faye","family":"Chapelle","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Immunology, Evelina Children Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon B.","family":"Drysdale","sequence":"additional","affiliation":[{"name":"St George\u2019s University Hospitals NHS Foundation Trust, London, United Kingdom"},{"name":"Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke","family":"Emonts","sequence":"additional","affiliation":[{"name":"Department of Paediatric Immunology, Infectious Diseases and Allergy, Great North Children\u2019s Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom"},{"name":"Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paddy","family":"McMaster","sequence":"additional","affiliation":[{"name":"Department of Paediatric Infectious Diseases, Royal Manchester Childrens\u00b4 Hospital, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Paulus","sequence":"additional","affiliation":[{"name":"Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom"},{"name":"Institute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Paediatric Infectious Diseases, University Hospital Southampton NHS Foundation Trust, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menie","family":"Rompola","sequence":"additional","affiliation":[{"name":"Dept. of Paediatric Haematology and Oncology, Leeds General Infirmary, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Vergnano","sequence":"additional","affiliation":[{"name":"Department of Paediatric Infectious Diseases, Bristol Royal Hospital for Children, Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Whittaker","sequence":"additional","affiliation":[{"name":"Paediatric Infectious Diseases, Imperial College Healthcare NHS Trust and Section of Paediatrics, Department of Infectious Diseases, Imperial College, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adilia","family":"Warris","sequence":"additional","affiliation":[{"name":"Medical Research Council Centre for Medical Mycology, University of Exeter, United Kingdom"},{"name":"Department of Paediatric Infectious Diseases, Great Ormond Street Hospital for Children, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,11,11]]},"reference":[{"key":"R1-20250615","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1128\/AAC.04109-14","article-title":"Systemic antifungal prescribing in neonates and children: outcomes from the antibiotic resistance and prescribing in European Children (ARPEC) Study.","volume":"59","author":"Lestner","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"R2-20250615","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1097\/INF.0000000000002463","article-title":"Neonatal antifungal consumption is dominated by prophylactic use; outcomes from the pediatric antifungal stewardship: optimizing antifungal prescription study.","volume":"38","author":"Ferreras-Antol\u00edn","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"R3-20250615","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1080\/21505594.2016.1226721","article-title":"Antifungal stewardship considerations for adults and pediatrics.","volume":"8","author":"Hamdy","year":"2017","journal-title":"Virulence"},{"key":"R4-20250615","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/jpids\/pix046","article-title":"Epidemiology of invasive fungal disease in children.","volume":"6","author":"Pana","year":"2018","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R5-20250615","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/cid\/cix687","article-title":"Call for action: invasive fungal infections associated with ibrutinib and other small molecule kinase inhibitors targeting immune signaling pathways.","volume":"66","author":"Chamilos","year":"2018","journal-title":"Clin Infect Dis"},{"key":"R6-20250615","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1016\/S0140-6736(03)14904-5","article-title":"Glucocorticoids and invasive fungal infections.","volume":"362","author":"Lionakis","year":"2003","journal-title":"Lancet"},{"key":"R7-20250615","doi-asserted-by":"crossref","first-page":"e0140930","DOI":"10.1371\/journal.pone.0140930","article-title":"Meta-analysis and cost comparison of empirical versus pre-emptive antifungal strategies in hematologic malignancy patients with high-risk febrile neutropenia.","volume":"10","author":"Fung","year":"2015","journal-title":"PLoS One"},{"key":"R8-20250615","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3201\/eid2106.140717","article-title":"Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus.","volume":"21","author":"van der Linden","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"R9-20250615","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12941-019-0323-z","article-title":"A systematic review of the impact of antifungal stewardship interventions in the United States.","volume":"18","author":"Hart","year":"2019","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"R10-20250615","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/jac\/dkx388","article-title":"A systematic review of interventions and performance measures for antifungal stewardship programmes.","volume":"73","author":"Bienvenu","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"R11-20250615","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/jac\/dky389","article-title":"Effectiveness of an antifungal stewardship programme at a London teaching hospital 2010-16.","volume":"74","author":"Whitney","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"R12-20250615","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S1470-2045(14)70017-8","article-title":"Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation.","volume":"15","author":"Groll","year":"2014","journal-title":"Lancet Oncol"},{"key":"R13-20250615","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.cmi.2019.05.019","article-title":"ESCMID-ECMM guideline: diagnosis and management of invasive aspergillosis in neonates and children.","volume":"25","author":"Warris","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"R14-20250615","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium.","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"R15-20250615","doi-asserted-by":"crossref","first-page":"i37","DOI":"10.1093\/jac\/dkq440","article-title":"Treatment and timing in invasive mould disease.","volume":"66","author":"Maertens","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"suppl_1","key":"R16-20250615","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1093\/jpids\/pix053","article-title":"Recognition and clinical presentation of invasive fungal disease in neonates and children.","volume":"6","author":"King","year":"2017","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"Suppl 7","key":"R17-20250615","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/1469-0691.12040","article-title":"ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp.","volume":"18","author":"Hope","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"R18-20250615","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1749-6632.2012.06829.x","article-title":"Risk stratification for invasive aspergillosis in immunocompromised patients.","volume":"1272","author":"Herbrecht","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"R19-20250615","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/myc.12990","article-title":"Epidemiology and outcome of invasive fungal disease in children after hematopoietic cell transplantation or treated for malignancy: impact of national programme of antifungal prophylaxis.","volume":"62","author":"Czy\u017cewski","year":"2019","journal-title":"Mycoses"},{"key":"R20-20250615","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/jpids\/pix030","article-title":"Risk factors for invasive fungal disease in pediatric cancer and hematopoietic stem cell transplantation: a systematic review.","volume":"7","author":"Fisher","year":"2018","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R21-20250615","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/bmt.2013.136","article-title":"Predictors of invasive fungal infection in pediatric allogeneic hematopoietic SCT recipients.","volume":"49","author":"Hol","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"R22-20250615","doi-asserted-by":"crossref","first-page":"e187","DOI":"10.1097\/INF.0000000000000274","article-title":"Per-species risk factors and predictors of invasive Candida infections in patients admitted to pediatric intensive care units: development of ERICAP scoring systems.","volume":"33","author":"Jordan","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"R23-20250615","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1097\/INF.0000000000001277","article-title":"Risk adjustment for congenital heart surgery score as a risk factor for candidemia in children undergoing congenital heart defect surgery.","volume":"35","author":"de Araujo Motta","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"R24-20250615","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1086\/655698","article-title":"Risk factors and predictors for candidemia in pediatric intensive care unit patients: implications for prevention.","volume":"51","author":"Zaoutis","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R25-20250615","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1093\/jpids\/piv024","article-title":"Failure to validate a multivariable clinical prediction model to identify pediatric intensive care unit patients at high risk for candidemia.","volume":"5","author":"Fisher","year":"2016","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R26-20250615","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jinf.2019.04.002","article-title":"Development and internal validation of a model for predicting 60-day risk of invasive mould disease in patients with haematological malignancies.","volume":"78","author":"Stanzani","year":"2019","journal-title":"J Infect"},{"key":"R27-20250615","first-page":"1868","article-title":"Liposomal amphotericin B twice weekly as antifungal prophylaxis in paediatric haematological malignancy patients.","volume":"17","author":"Bochennek","year":"2011","journal-title":"Mycology"},{"key":"R28-20250615","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1097\/INF.0000000000000335","article-title":"Safety and tolerability of high-dose weekly liposomal amphotericin B antifungal prophylaxis.","volume":"33","author":"Hand","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"R29-20250615","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1200\/JCO.2016.71.7017","article-title":"Guideline for the management of fever and neutropenia in children with cancer and hematopoietic stem-cell transplantation recipients: 2017 update.","volume":"35","author":"Lehrnbecher","year":"2017","journal-title":"J Clin Oncol"},{"key":"R30-20250615","first-page":"CD006343","article-title":"Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections.","volume":"2","author":"Blyth","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"R31-20250615","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/INF.0000000000000101","article-title":"Role of management strategies in reducing mortality from invasive fungal disease in children with cancer or receiving hemopoietic stem cell transplant: a single center 30-year experience.","volume":"33","author":"Castagnola","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"R32-20250615","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1093\/jac\/dky244","article-title":"Efficacy of pre-emptive versus empirical antifungal therapy in children with cancer and high-risk febrile neutropenia: a randomized clinical trial.","volume":"73","author":"Santolaya","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"R33-20250615","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/INF.0000000000002317","article-title":"Management of invasive fungal disease in neonates and children.","volume":"38","author":"Ferreras-Antolin","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"R34-20250615","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1473-3099(15)70006-X","article-title":"British Society for Medical Mycology best practice recommendations for the diagnosis of serious fungal diseases.","volume":"15","author":"Schelenz","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"R35-20250615","doi-asserted-by":"crossref","first-page":"e27963","DOI":"10.1002\/pbc.27963","article-title":"Effect of an intervention to improve the prescription of antifungals in pediatric hematology-oncology.","volume":"67","author":"Santiago-Garc\u00eda","year":"2020","journal-title":"Pediatr Blood Cancer"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003402","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T12:01:47Z","timestamp":1749988907000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,11]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000003402","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11,11]]}}}